These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 17187079)

  • 1. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.
    Lieberman RL; Wustman BA; Huertas P; Powe AC; Pine CW; Khanna R; Schlossmacher MG; Ringe D; Petsko GA
    Nat Chem Biol; 2007 Feb; 3(2):101-7. PubMed ID: 17187079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Getting into the fold.
    Brooks DA
    Nat Chem Biol; 2007 Feb; 3(2):84-5. PubMed ID: 17235342
    [No Abstract]   [Full Text] [Related]  

  • 3. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase.
    Khanna R; Benjamin ER; Pellegrino L; Schilling A; Rigat BA; Soska R; Nafar H; Ranes BE; Feng J; Lun Y; Powe AC; Palling DJ; Wustman BA; Schiffmann R; Mahuran DJ; Lockhart DJ; Valenzano KJ
    FEBS J; 2010 Apr; 277(7):1618-38. PubMed ID: 20148966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.
    Sun Y; Liou B; Xu YH; Quinn B; Zhang W; Hamler R; Setchell KD; Grabowski GA
    J Biol Chem; 2012 Feb; 287(6):4275-87. PubMed ID: 22167193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isofagomine induced stabilization of glucocerebrosidase.
    Kornhaber GJ; Tropak MB; Maegawa GH; Tuske SJ; Coales SJ; Mahuran DJ; Hamuro Y
    Chembiochem; 2008 Nov; 9(16):2643-9. PubMed ID: 18932186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms.
    Steet RA; Chung S; Wustman B; Powe A; Do H; Kornfeld SA
    Proc Natl Acad Sci U S A; 2006 Sep; 103(37):13813-8. PubMed ID: 16945909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease.
    Orwig SD; Tan YL; Grimster NP; Yu Z; Powers ET; Kelly JW; Lieberman RL
    Biochemistry; 2011 Dec; 50(49):10647-57. PubMed ID: 22047104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability.
    Lieberman RL; D'aquino JA; Ringe D; Petsko GA
    Biochemistry; 2009 Jun; 48(22):4816-27. PubMed ID: 19374450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease.
    Serra-Vinardell J; Díaz L; Gutiérrez-de Terán H; Sánchez-Ollé G; Bujons J; Michelakakis H; Mavridou I; Aerts JM; Delgado A; Grinberg D; Vilageliu L; Casas J
    Int J Biochem Cell Biol; 2014 Sep; 54():245-54. PubMed ID: 25084554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.
    Maegawa GH; Tropak MB; Buttner JD; Rigat BA; Fuller M; Pandit D; Tang L; Kornhaber GJ; Hamuro Y; Clarke JT; Mahuran DJ
    J Biol Chem; 2009 Aug; 284(35):23502-16. PubMed ID: 19578116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.
    Tropak MB; Kornhaber GJ; Rigat BA; Maegawa GH; Buttner JD; Blanchard JE; Murphy C; Tuske SJ; Coales SJ; Hamuro Y; Brown ED; Mahuran DJ
    Chembiochem; 2008 Nov; 9(16):2650-62. PubMed ID: 18972510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the N370S mutant of glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.
    Tang L; Coales SJ; Morrow JA; Edmunds T; Hamuro Y
    Chembiochem; 2012 Oct; 13(15):2243-50. PubMed ID: 22961873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells.
    Trapero A; Alfonso I; Butters TD; Llebaria A
    J Am Chem Soc; 2011 Apr; 133(14):5474-84. PubMed ID: 21413704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. X-ray and biochemical analysis of N370S mutant human acid β-glucosidase.
    Wei RR; Hughes H; Boucher S; Bird JJ; Guziewicz N; Van Patten SM; Qiu H; Pan CQ; Edmunds T
    J Biol Chem; 2011 Jan; 286(1):299-308. PubMed ID: 20980263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The N370S (Asn370-->Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C.
    Salvioli R; Tatti M; Scarpa S; Moavero SM; Ciaffoni F; Felicetti F; Kaneski CR; Brady RO; Vaccaro AM
    Biochem J; 2005 Aug; 390(Pt 1):95-103. PubMed ID: 15826241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase.
    Steet R; Chung S; Lee WS; Pine CW; Do H; Kornfeld S
    Biochem Pharmacol; 2007 May; 73(9):1376-83. PubMed ID: 17217920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imino- and Azasugar Protonation Inside Human Acid β-Glucosidase, the Enzyme that is Defective in Gaucher Disease.
    Matassini C; Warren J; Wang B; Goti A; Cardona F; Morrone A; Bols M
    Angew Chem Int Ed Engl; 2020 Jun; 59(26):10466-10469. PubMed ID: 32191378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.
    Yu Z; Sawkar AR; Whalen LJ; Wong CH; Kelly JW
    J Med Chem; 2007 Jan; 50(1):94-100. PubMed ID: 17201413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease.
    Li Z; Li T; Dai S; Xie X; Ma X; Zhao W; Zhang W; Li J; Wang PG
    Chembiochem; 2013 Jul; 14(10):1239-47. PubMed ID: 23775891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bicyclic derivatives of L-idonojirimycin as pharmacological chaperones for neuronopathic forms of Gaucher disease.
    Alfonso P; Andreu V; Pino-Angeles A; Moya-García AA; García-Moreno MI; Rodríguez-Rey JC; Sánchez-Jiménez F; Pocoví M; Ortiz Mellet C; García Fernández JM; Giraldo P
    Chembiochem; 2013 May; 14(8):943-9. PubMed ID: 23606264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.